FzioMed wins independent review of Oxiplex gel

November 4, 2013 by Brad Perriello

FzioMed wins an independent review of the pre-market approval application for its Oxiplex spinal surgery gel that the FDA denied in 2008.

FzioMed wins independent review of Oxiplex gel

FzioMed said the FDA granted an independent review of its pre-market approval application for the Oxiplex spinal surgery gel.

San Luis Obispo, Calif.-based FzioMed originally filed its PMA application for Oxiplex in October 2007. The FDA responded with a "not approvable letter" back in July 2008 after determining that FzioMed hadn't provided sufficient evidence of the gel's effectiveness in aiding in healing following lower back spinal surgery.

Last December the medical device company filed a citizen's petition asking for a reconsideration of the PMA application.

Sign up to get our free newsletters delivered straight to your inbox

The independent review nod from the FDA means that a Medical Devices Dispute Resolution Panel is slated to be convened to advise FDA commissioner Dr. Margaret Hamburg on whether to reverse the watchdog agency's rejection of the Oxiplex PMA, FzioMed said.

"We commend the FDA for granting our petition for reconsideration, a rarely used part of the regulatory process that companies can pursue when their device application is denied by the FDA," FzioMed president & CEO John Krelle said in prepared remarks. "The totality of data from the various studies submitted to FDA on Oxiplex, representing approximately 500 patients studied over nearly a decade, combined with extensive clinical success achieved outside the U.S., demonstrate that Oxiplex can offer increased effectiveness compared to spine surgery alone, while presenting no significant safety risk."